Keywords: Pfizer, Biocad, Factor VIII, Hemophilia, Pharm-sintez, Cancer drug manufacturing, Russia

Pfizer to transfer Factor VIII license to Russia's Biocad; Pharm-sintez cancer plans

Article | 26 June 2012

Print This

US drug behemoth Pfizer (NYSE: PFE) is finalizing confidions for the transfer of a license for the production of Factor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in